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Abstract
Three variants of the confidence set inference (CSI) procedure were proposed and applied to both
the simulated and the Collaborative Study on the Genetics of Alcoholism (COGA) data. For each
of the two applications, we first performed a preliminary genome scan study based on the
microsatellite markers using the GENEHUNTER+ software to identify regions that potentially
harbor disease loci. For each such region, we estimated the sibling identity-by-descent sharing
probability distribution at the putative disease locus. Based on these estimated probabilities, the
CSI procedures were employed to further localize the disease loci using the single-nucleotide
polymorphism markers, leading to confidence intervals/regions for their locations. For our analysis
with the simulated data, we had knowledge of the simulating models at the time we performed the
analysis.
Background
A frequently used strategy in linkage analysis is to first
screen the entire genome using microsatellite (MS) mark-
ers, and then to follow up on preliminary linkage regions
using densely saturated (often single-nucleotide polymor-
phisms (SNP)) markers. Although many statistical meth-
ods are available for each step of this two-stage approach,
only a limited number of them (e.g., Liang et al. [1]) are
able to provide confidence estimates of disease gene loca-
tions. Furthermore, most of the methods available are
subject to multiplicity adjustment, which is a non-trivial
matter given the complex dependency of the statistics
involved.
The confidence set inference (CSI) procedure [2] can be
used to obtain confidence estimates using affected sib-
pair (ASP) data, and avoids the multiple testing problem.
Unlike the approach of Liang et al. [1], it is not based on
the asymptotic distribution of the estimator of the loca-
tion of the trait locus. Instead, it indirectly deduces a con-
fidence region for the trait locus based upon a set of
markers that are inferred to be within a pre-specified dis-
tance from the trait locus. Note that this is a non-direc-
tional procedure that makes no distinction between loci
symmetrically located around a marker. In the present
paper, we explore three variants of the CSI procedure to
further improve its performance. The first modification is
to test every location (not just the markers) in the region
of interest. This practice effectively eliminates the "non-
directional" problem of the original CSI method. The sec-
ond variant is a multipoint extension of the first variant,
in that information from all markers are utilized to calcu-
late the IBD sharing statistic at a marker locus. The last is
also a multipoint approach, but the identity-by-descent
(IBD) sharing statistic is calculated at each hypothesized
disease locus rather than at its nearest marker locus.
from Genetic Analysis Workshop 14: Microsatellite and single-nucleotide polymorphism
Noordwijkerhout, The Netherlands, 7-10 September 2004
Published: 30 December 2005
BMC Genetics 2005, 6(Suppl 1):S21 doi:10.1186/1471-2156-6-S1-S21
<supplement> <title> <p>Genetic Analysis Workshop 14: Microsatellite and single-nucleotide polymorphism</p> </title> <editor>Joan E Bailey-Wilson, Laura Almasy, Mariza de Andrade, Julia Bailey, Heike Bickeböller, Heather J Cordell, E Warwick Daw, Lynn Goldin, Ellen L Goode, Courtney Gray- McGuire, Wayne Hening, Gail Jarvik, Brion S Maher, Nancy Mendell, Andrew D Paterson, John Rice, Glen Satten, Brian Suarez, Veronica Vieland, Marsha Wilcox, Heping Zhang, Andreas Ziegler and Jean W MacCluer</editor> <note>Proceedings</note> </supplement>BMC Genetics 2005, 6:S21
Page 2 of 5
(page number not for citation purposes)
Methods
Confidence set inference
This is a two-point approach that tests the following
hypotheses for each marker m:
H0m : θm ≤ θ0 vs. Ham: θm > θ0,
where θm denotes the true, but unknown, recombination
fraction between the disease locus and marker m, and θ0 is
a predetermined recombination fraction. Note that the
above null and alternative hypotheses are the reversals of
those in traditional linkage analysis. It is actually this for-
mulation that allows us to construct the confidence region
for the location of the trait locus [2,3]. For testing the
above hypotheses with ASP data, we use the mean statistic
[4] because it has been shown to perform well under a
wide variety of disease models [3,4]. Recently, Elston et al.
[5] suggested that, when there is actually no linkage, the
average IBD sharing between sib pairs in an ASP-only
design maybe higher than what would be expected under
the traditional null hypothesis of no linkage. Because our
null hypothesis assumes tight linkage, the effect of such
phenomenon on our method is unclear, and thus further
investigation is needed.
Let L be the set of markers for which the corresponding
null hypotheses are not rejected at level α. Then the prob-
ability that L includes at least one marker located within
θ0 from the disease locus is at least (1 – α). From this set
of markers, we can deduce the following confidence
region for the disease locus:
where τm is the map position of marker m, while d (θ0) is
the genetic distance that corresponds to recombination
fraction θ0. In practice, θ0 is usually chosen to correspond
to half of the maximum distance between any two adja-
cent markers in the region to be investigated.
Variant I (CSI-v1): testing at an arbitrary locus
For an arbitrary location τ  in the preliminary linkage
region, we test the following hypotheses:
H0m : τ = τ* vs. Ham : τ ≠ τ*
where τ* is the true location of the disease locus in the
region, and m is the marker closest to τ. The following is
our strategy for carrying out these tests. First, we consider
a finite number of loci (say, at 1 cM density) in the region.
For each of these loci, we test whether the IBD sharing at
the nearest marker locus m is within the margin of error
from what is expected if the disease locus is indeed at τ
(the null hypothesis). We then iteratively refine the discre-
tization strategy so that the locations for which the null
hypotheses are not rejected constitute a (union of) "con-
tinuous" chromosomal segment(s).
Variant II (CSI-v2): multipoint extension
This is the multipoint extension of CSI-v1. The hypotheses
and the discretization/ search strategies are the same as
before. However, when calculating the observed sharing
statistic at the nearest marker locus m, information from
all markers, not just marker m itself, are used.
Variant III (CSI-v3): multipoint extension with sharing 
statistic
This is another multipoint extension with the same
hypotheses as in CSI-v1 and CSI-v2, but the observed
sharing statistic is calculated at the hypothesized locus
itself given all the observed marker data.
Estimation of IBD sharing probabilities at putative disease 
loci
In Papachristou and Lin [2], the IBD sharing probabilities
are estimated through the use of population risk charac-
teristics (disease prevalence, relative risks for offspring
and sibling), which are frequently available from popula-
tion epidemiological studies. Alternatively, these proba-
bilities can be estimated directly from the current data
after preliminary linkage regions are established. Let τ be
the putative disease locus (at which the maximum score
occurs) in a linkage region, and zk, k = 0, 1, 2, be the prob-
abilities that an ASP shares k alleles IBD at τ. Then, the
likelihood of zk is
where n is the number of ASPs in the study. Note that the
likelihood is parameterized in terms of z1 and z2 only,
since z0 is completely determined by the other two. For
more details on the computation of the above likelihood
the reader is referred to Kruglyak et al. [6]. The zk values
that maximize the above likelihood (obtained using the
EM algorithm) are taken as estimates of the IBD probabil-
ities.
Data and phenotypes
For all four simulated populations, we extracted all possi-
ble families with at least two affected children. For fami-
lies with three or more affected children all possible pairs
were formed and were treated as if they were independent
nuclear families. This method yielded an average of 150,
170, 150, and 180 ASPs for the AI, DA, KA, and NYC pop-
ulations, respectively. For the application to the Collabo-
rative Study on the Genetic Analysis of Alcoholism
(COGA) data, ASPs were also extracted from the extended
pedigrees, yielding a sample of 551 pairs. The ALDX1
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diagnostic criterion was used, and only those who were
confirmed to be affected were used in our study.
Selection of SNPs in the linkage regions
After linkage regions are identified using the method of
Kong and Cox (KAC) [7] as implemented in GENE-
HUNTER+, a variant of GENEHUNTER [6], SNPs sur-
rounding the maximum KAC scores are selected for CSI
analyses. For chromosome 1 in the simulated data, we use
20 SNP markers, ten on each side of the maximum KAC
score, that cover a region of about 60 cM. Because the
regions on chromosomes 5 and 9 are usually maximized
at the beginning of the chromosomes, we use the first 15
available SNP markers that are spread over a region of
about 55 cM. On the other hand, the linkage regions on
chromosome 3 are usually maximized at the end of chro-
mosome 3, so we use the last 15 SNP markers of the chro-
mosome that spanned a region of 45 cM. For the COGA
data, for each chromosome with a maximum KAC score
exceeding the threshold, we used all the Illumina SNPs
within 30 cM (or less if the end of a chromosome is
encountered as in chromosome 12) on each side of the
maximum score for CSI analyses.
Results
Simulated data
First, the KAC scores were calculated using the MS markers
throughout the whole genome. Only chromosomes 1, 3,
5, and 9 yielded significant results using the threshold of
3.09 (corresponding to a pointwise significant level of
0.001) for more than one-third of the replicates in any of
the populations. Therefore, we decided to focus on those
4 chromosomes for obtaining confidence regions using
CSI and its variants based on the 3-cM-density SNPs.
From the clinical ascertainment scheme, DA would be
most informative for a locus influencing the behavioral
symptoms. It turns out that, in the simulating model,
locus D1 (on chromosome 1) plays an important role in
the trait relating to these symptoms. Indeed, the KAC
results reveal that only population DA has a majority of
the replicates (in fact, all 100 of them) showing linkage at
the pointwise significance level of 0.001. Among the other
three populations, only AI has more than one-third of the
replicates (45) showing significant results. Similarly, as
expected from the ascertainment schemes, all four popu-
lations contain information about the disease gene on
Table 1: Percentagesa of CSI confidence regions including disease genes. The average length (L) and the standard deviation (SD) of the 
lengths of the confidence regions are also provided.
Population
AI DA KA NYC
Gene Method % L SD % L SD % L SD % L SD
D 1C S I 1 0 0 5 9 . 8 7 . 2 1 0 0 5 4 . 5 8 . 1 ------
C S I - v 1 9 3 5 5 . 6 7 . 5 9 5 4 6 . 8 8 . 7 ------
C S I - v 2 1 0 0 4 8 . 4 1 2 . 8 9 9 3 6 . 4 1 2 . 8 ------
C S I - v 3 1 0 0 4 9 . 2 1 2 . 6 9 7 3 7 . 0 1 2 . 2 ------
D2 CSI 97 39.5 5.8 99 38.0 5.8 100 39.4 5.3 98 37.5 6.0
CSI-v1 92 36.1 7.2 91 34.4 6.9 95 36.5 6.4 88 34.1 7.5
CSI-v2 100 29.2 10.8 99 26.3 8.6 100 29.9 9.6 98 28.8 10.1
CSI-v3 100 29.8 10.8 100 26.9 8.4 100 30.7 9.4 98 29.0 9.8
D3 CSI 98 39.3 5.8 - - - 100 38.6 4.7 - - -
CSI-v1 92 36.9 5.6 - - - 100 36.1 5.3 - - -
CSI-v2 100 31.2 9.8 - - - 100 28.9 10.4 - - -
CSI-v3 100 31.7 9.5 - - - 100 29.2 10.4 - - -
D4 CSI 94 39.2 5.6 - - - 96 38.6 5.1 - - -
CSI-v1 94 36.8 5.9 - - - 93 36.0 5.2 - - -
CSI-v2 100 31.5 9.5 - - - 100 29.9 8.5 - - -
CSI-v3 100 31.7 9.4 - - - 100 30.1 8.5 - - -
a These are percentages of replicates among those that have been inferred to be linked by KAC at the threshold of 3.09. For each disease gene, if 
data from a particular population did not lead to inferences of significance linkage for at least one-third of the replicates, the results for that 
population are not included.BMC Genetics 2005, 6:S21
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chromosome 3, and thus they all have more than one-
third of the replicates (61, 82, 39, and 50 for AI, DA, KA,
and NYC, respectively) with significant results. For the
genes on chromosomes 5 and 9, on the other hand, only
AI and KA contain information about their locations.
Again, the results are consistent with the simulating
model in that KA is more informative about these two loci
than AI (77 vs. 48 for D3, and 76 vs. 36 for D4). Surpris-
ingly, more than two-thirds of the replicates from NYC are
not informative for these loci.
Table 1 presents the results from the four CSI procedures
with a preset 95% coverage probability. For each disease
locus, only populations that are informative for linkage
for at least one-third of the replicates are investigated. As
can be seen from the results, the original CSI method
indeed produced wide regions. On the other hand, the
two multipoint variants (CSI-v2 and CSI-v3) have consid-
erably narrower regions, with almost all of them includ-
ing the true disease locations.
The COGA dataset
Whole-genome screening using KAC based on the MS
markers resulted in 6 chromosomal regions (one of each
on chromosomes 1, 2, 6, 11, 12, and 15) with the maxi-
mum KAC scores exceeding the cutoff of 2.33 (a pointwise
significant level of 0.01). As with the simulated data, our
analysis scheme, after preliminary linkages are estab-
lished, is to use the SNPs data to further narrow down the
linkage regions. Specifically, the four CSI procedures, all
with 95% coverage probability, were used to construct
confidence regions for the disease gene locations. How-
Results from the COGA dataset. Figure 1
Results from the COGA dataset. The curve on each plot represents the KAC scores (using MS markers) in the prelimi-
nary linkage regions plotted again the SNP map. The four confidence regions (line segments) plotted below the curve are the 
results from the four CSI procedures using the SNPs, as identified in the legend of the figure. In particular, the confidence 
regions inferred from CSI-v3 for chromosomes 2, 6, 11, and 12 are, respectively, C2 = [82.4, 83.3] ∪ [84.1, 84.2] ∪ {84.4} ∪ 
[84.6, 127.4] ∪ [127.5, 143.8], C6 = [117.3, 117.7] ∪ [121.1, 121.8] ∪ [121.9, 122.1] ∪ [126.2, 126.4], C11 = [119.3, 119.7] ∪ 
[120.2, 120.4] ∪ [121.0, 121.2] ∪ [122.9, 134.3], and C12 = [171.8, 173.7] ∪ [174.1, 176.2] ∪ [176.3, 179.7]Publish with BioMed Central    and   every 
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ever, chromosomes 1 and 15 are not included in the CSI
analysis as there are no SNPs in the preliminary linkage
regions (toward the ends) on these two chromosomes.
Figure 1 shows the results for the remaining four chromo-
somes focusing on the linkage regions. For chromosomes
6, 11, and 12, the results demonstrate the abilities of the
two multipoint CSI methods for narrowing down the
linkage regions. In particular, CSI-v3 narrows the regions
on these three chromosomes to 1.5, 12.3, and 7.4 cM,
respectively. However, for chromosome 2, the two
multipoint procedures failed to narrow further from the
two-point regions. By inspecting the KAC scores in the
region, it appears that there are potentially multiple dis-
ease loci in the region, which might, in part, explain the
CSI results.
Discussion
The purpose of this contribution is two-fold. First, we
want to demonstrate that, unlike most of other linkage
methods, confidence regions with pre-specified coverage
probabilities can be obtained by the CSI procedures. This
is especially useful following preliminary linkage analysis.
Specifically, after linkage is established, dense SNP mark-
ers can be genotyped in the linkage regions so that the CSI
procedures can then be applied, perhaps as an intermedi-
ate mapping method before fine mapping association
studies commence. Second, through the analyses of both
the simulated and the COGA data, we show that the CSI
procedure [2] can be further refined to provide narrower
confidence regions for disease gene locations. We are
highly encouraged by the extremely high actual coverage
probabilities for the two multipoint CSI procedures, as
can be seen from the simulated data. This would also give
us confidence in results from real applications.
For the COGA dataset, we are able to place the disease loci
on three of the chromosomes to narrow confidence
regions using CSI-v3 (ranging from 1.5 cM to 12.3 cM in
length), which may have potential implications in study-
ing the genetics of alcoholism. For the simulated data,
however, the confidence regions are still quite large
(around 30 cM for most of them) with the two multipoint
variants. We speculate that this is mainly due to the lim-
ited informativeness of the still quite sparse 3-cM-density
SNP markers. We believe that, with a much denser SNP
map (say one with 0.25–0.5 cM inter-marker separation),
further narrowing can be achieved. Moreover, we also
plan to explore other methods for estimating relative risks
(or IBD probability distributions at disease loci) to exam-
ine their effects on the results from the CSI procedures.
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